#USA #New York #Lawsuit #ADMA Biologics #Jerrold Grossman

Overview of the ADMA Biologics Lawsuit

In recent developments within the securities market, investors have been alerted to a significant lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA). This legal action involves allegations against the company's Vice Chairman, Jerrold V. Grossman. Investors who purchased ADMA securities between August 9, 2024, and March 25, 2026, may have a chance to recover losses incurred during this period. The lead plaintiff deadline for this class action suit is set for August 10, 2026.

Jerrold V. Grossman's Involvement

Jerrold Grossman, a co-founder and influential figure in ADMA, has been named as a defendant in this lawsuit. The complaint points to his signature on annual reports from 2024 and 2025 that allegedly included false statements regarding revenue recognition and undisclosed related party transactions. Specifically, the complaint references the operations of Genesis BioPharma Services, a business apparently controlled by Grossman that functioned as an undisclosed distributor out of ADMA's own facilities.

Throughout the specified class period, it is contended that Grossman had the authority to influence the content of the company's SEC filings. His role extended to being privy to confidential business information and overseeing compliance with disclosure obligations.

According to legal representatives, any corporate officer who signs SEC documents bears responsibility for ensuring the accuracy of the information. Therefore, the inclusion of misleading disclosures in annual reports can result in considerable personal liability. This situation underscores the importance of transparency and ethical governance in publicly traded companies.

Allegations Against ADMA Biologics

The core of the complaint describes how Genesis BioPharma Services, linked to Grossman and operating from ADMA's headquarters, was utilized to sell ADSENIV products without being disclosed as a related party. Instead, ADMA's filings reflected transactions only with its disclosed vendor, GenesisBPS, which is also owned by Grossman’s family.

This lack of transparency raises serious questions about the management's adherence to ethical reporting practices. Given the interconnected nature of these entities, the failure to acknowledge correct dealings could sway investors' decisions and affect their financial interests adversely. Throughout the timeframe in question, multiple SEC filings reportedly lacked proper disclosures.

Who Can Join the Class Action?

Investors who purchased shares of ADMA during the stated period and incurred losses are encouraged to act. Eligibility criteria focus on transaction dates rather than whether the shares are currently held. Thus, even investors who sold their shares at a loss may still partake in the case. Participation entails no upfront costs, as lawsuits of this nature typically adhere to a contingency model.

To initiate a claim, interested parties can fill out a form on the SueWallSt website or reach out to their legal representatives via the contact information provided. Legal assistance is crucial in navigating the complexities of this lawsuit and maximizing recovery potential for affected investors.

Conclusion

As ADMA Biologics faces legal scrutiny, shareholders must remain vigilant and informed. The upcoming deadlines for the class action suit serve as a reminder of the importance of shareholder rights and corporate accountability. By acting swiftly, investors can safeguard their interests and contribute to broader efforts to uphold the integrity of financial markets. For updates regarding the lawsuit and further instructions on participation, continue to monitor relevant communications from SueWallSt and legal counsel.

For more information on participating in this lawsuit, investors can contact Levi Korsinsky LLP at (888) SueWallSt or email at [email protected]. This is an opportunity that investors should not overlook, ensuring they are protected against any mismanagement or misconduct carried out during the criticized period.